Father Appeals to Russia for Experimental Cancer Vaccine Trial to Save 21-Year-Old Son's Life

Manu Srivastava, father of 21-year-old Ansh Srivastava who is battling cancer, has received a response from the Russian government regarding his heartfelt appeal for help.

The Russian authorities have taken a compassionate stance on the Lucknow father's request to save his son's life through an experimental cancer vaccine.

In an interview with ANI, Manu Srivastava explained that the promising cancer vaccine developed in Russia is not yet available in India, prompting him to reach out to the Russian government to consider including his son in their clinical trials.

"My son was diagnosed with stage four cancer and is currently undergoing treatment here. However, the doctors haven't been completely reassuring about his prognosis, leaving me deeply concerned due to the uncertainty," Srivastava told ANI.

He continued, "After learning about a highly effective cancer vaccine developed in Russia, I sent formal requests to both the Indian government and Russian authorities. I received a response indicating my request was under consideration and had been forwarded to Russia's Ministry of Health for further review."

The desperate father also contacted Indian officials regarding the possibility of accessing the Russian vaccine. The response confirmed that the vaccine is currently only being administered within Russia, with trials limited to local participants.

"The Indian government informed us that the vaccine manufactured in Russia is currently only being implemented there. The clinical trials involve only local participants, and neither India nor any other country has received approval to conduct trials yet," he added.

In his comprehensive approach, Manu Srivastava wrote appeals to Prime Minister Narendra Modi, Uttar Pradesh Chief Minister Yogi Adityanath, the Union Health Minister, and senior officials in both Russia and South Korea, requesting that his son Ansh be included in the Russian cancer vaccine trials.

On October 27, the Government of the Russian Federation sent an official letter responding to his appeal.

According to a September 7 report by Tass, Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), announced at the Eastern Economic Forum (EEF) that Russia's cancer vaccine has successfully completed preclinical trials, showing both safety and high efficacy.

Skvortsova emphasized that preclinical results confirmed the vaccine's safety, even with repeated administration, and demonstrated significant effectiveness. Researchers observed tumor size reductions and slower progression rates ranging from 60% to 80%, depending on specific disease characteristics. The studies also indicated improved survival rates attributed to the vaccine.